A stable latent reservoir for HIV-1 in resting CD4+ T cells precludes cure. Curative strategies targeting the reservoir are being tested and require accurate, scalable reservoir assays. The reservoir was originally defined with a quantitative viral outgrowth assays (QVOA) for cells releasing infectious virus following one round of T cell activation. This assay requires growing virus from individual latently infected cells and is costly and time consuming. Therefore, many studies have used DNA PCR to detect HIV-1 proviruses in infected cells or RT-PCR to detect the induction of viral RNA production from latently infected cells. However, two fundamental findings have altered how we view reservoir measurements. The first is that the vast majority of HIV-1 proviruses are defective due to the presence of large deletions and/or APOBEC-mediated hypermutation, as revealed by near-full genome proviral sequencing. These defective proviruses cannot contribute to viral rebound and should not be considered part of the latent reservoir. Most PCR assays fail to distinguish intact and defective proviruses. Therefore, they dramatically overestimate reservoir size and should not be used. The second important finding is that not all intact proviruses are induced by a single round of in vitro T cells activation. Therefore, induction assays that measure viral outgrowth or viral RNA production after a single round of T cell activation will underestimate reservoir size. A conceptually novel approach to measuring the latent reservoir is to count all of the intact proviruses regardless of their transcriptional status at any particular time. This can be done with the intact proviral DNA assay (IPDA). More recently identified conceptual issues in reservoir measurement include the problem of clonal expansion. The reservoir is dominated by large clones of infected cells that wax and wane over time, and current measurements do not capture dynamic changes in reservoir composition. In addition, the relationship between the viruses that cause rebound following interruption of antiretroviral therapy and the viruses detected in various reservoir assays needs to be clarified. This talk will discuss these issues and summarize the current state of reservoir measurements.